International Journal of Cancer Management

Published by: Kowsar

The Differences of Age, Tumor Grade, and Her2 Amplification in Estrogen and Progesterone Receptor Status in Patients with Breast Cancer

Elnaz Sheikhpour 1 , * and Shokouh Taghipour 2
Authors Information
1 Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Article information
  • International Journal of Cancer Management: August 2018, 11 (8); e9492
  • Published Online: February 28, 2018
  • Article Type: Research Article
  • Received: October 26, 2016
  • Revised: February 4, 2017
  • Accepted: February 24, 2018
  • DOI: 10.5812/ijcm.9492

To Cite: Sheikhpour E, Taghipour S. The Differences of Age, Tumor Grade, and Her2 Amplification in Estrogen and Progesterone Receptor Status in Patients with Breast Cancer, Int J Cancer Manag. 2018 ; 11(8):e9492. doi: 10.5812/ijcm.9492.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Sheikhpour R, Ghassemi. N , Yaghmaei P. Immunohistochemical assessment of p53 protein and its correlation with clinicopathological parameters in patients with breast cancer. Indian J Scitechnol. 2014;7(4):472-9.
  • 2. Sheikhpour R, Mohiti Ardekani J. The effect of progesterone on P53 protein in T47D cell line [In Persian]. J Urmia Univ Med Sci. 2014;25(10):954-60.
  • 3. Ozguzer A, Bayol U, Pala EE, Akdeniz CY, Degirmenci M. Does single receptor positive breast carcinoma differ with regard to age, tumor grade, and HER2 amplification status? J BUON. 2016;21(1):21-6. [PubMed: 27061526].
  • 4. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4(3):192-208. doi: 10.1016/j.molonc.2010.04.004. [PubMed: 20452298].
  • 5. Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, et al. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med. 2005;23(3):189-94. [PubMed: 15940066].
  • 6. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol. 2001;12(4):525-33. doi: 10.1023/A:1011163211802. [PubMed: 11398888].
  • 7. Looi LM, Cheah PL. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malays J Pathol. 1998;20(1):19-23. [PubMed: 10879259].
  • 8. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001;10(3):139-52. doi: 10.1097/00019606-200109000-00001. [PubMed: 11552716].
  • 9. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973-9. doi: 10.1200/JCO.2003.09.099. [PubMed: 12743151].
  • 10. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17(12):1545-54. doi: 10.1038/modpathol.3800229. [PubMed: 15272277].
  • 11. Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119(1):53-61. doi: 10.1007/s10549-009-0318-0. [PubMed: 19205877].
  • 12. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006;106(12):2576-82. doi: 10.1002/cncr.21919. [PubMed: 16703595].
  • 13. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359-77. doi: 10.1038/bjc.1957.43. [PubMed: 13499785].
  • 14. Colomer R, Beltran M, Dorcas J, Cortes-Funes H, Hornedo J, Valentin V, et al. It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol. 2005;23(16):3868-9. author reply 3869-70. doi: 10.1200/JCO.2005.05.203. [PubMed: 15923595].
  • 15. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat. 1998;49(3):219-25. doi: 10.1023/A:1006011328655. [PubMed: 9776505].
  • 16. De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol. 2008;26(2):335-6. author reply 336-8. doi: 10.1200/JCO.2007.14.8411. [PubMed: 18182677].
  • 17. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21-7. doi: 10.1309/4WV79N2GHJ3X1841. [PubMed: 15762276].
  • 18. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;25(30):4772-8. doi: 10.1200/JCO.2007.12.2747. [PubMed: 17876012].
  • 19. Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol. 2009;62(1):95-6. doi: 10.1136/jcp.2008.060723. [PubMed: 19103868].
  • 20. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991;51(1):105-9. [PubMed: 1988075].
  • 21. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 1991;83(3):154-5. doi: 10.1093/jnci/83.3.154. [PubMed: 1988696].
  • 22. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217-33. doi: 10.1210/er.2006-0045. [PubMed: 18216219].
  • 23. Sundblad AS, Caprarulo L. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors]. Medicina (B Aires). 1996;56(6):683-9. [PubMed: 9284572].
  • 24. Ng CH, Pathy NB, Taib NA, Mun KS, Rhodes A, Yip CH. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pac J Cancer Prev. 2012;13(4):1111-3. doi: 10.7314/APJCP.2012.13.4.1111. [PubMed: 22799290].
  • 25. Chan M, Chang MC, Gonzalez R, Lategan B, del Barco E, Vera-Badillo F, et al. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS One. 2015;10(7). e0132449. doi: 10.1371/journal.pone.0132449. [PubMed: 26161666].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments